## Olivier Bruyere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9225837/publications.pdf

Version: 2024-02-01

458 papers 33,760 citations

7096 78 h-index 167 g-index

488 all docs 488 docs citations

488 times ranked 29667 citing authors

#	Article	IF	Citations
1	Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019, 48, 16-31.	1.6	6,824
2	Health-Related Quality of Life in Total Hip and Total Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2004, 86, 963-974.	3.0	1,481
3	Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet, The, 2001, 357, 251-256.	13.7	1,116
4	Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011, 22, 391-420.	3.1	893
5	Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0169548.	2.5	737
6	The Effects of Vitamin D on Skeletal Muscle Strength, Muscle Mass, and Muscle Power: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4336-4345.	3.6	503
7	Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. Women's Health, 2019, 15, 174550651984404.	1.5	488
8	Pitfalls in the measurement of muscle mass: a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 269-278.	<b>7.</b> 3	482
9	Sarcopenia in daily practice: assessment and management. BMC Geriatrics, 2016, 16, 170.	2.7	468
10	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	3.4	414
11	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	3.4	392
12	Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 2017, 28, 1817-1833.	3.1	381
13	Smart wearable body sensors for patient self-assessment and monitoring. Archives of Public Health, 2014, 72, 28.	2.4	333
14	Sarcopenia: burden and challenges for public health. Archives of Public Health, 2014, 72, 45.	2.4	317
15	Quality of Life in Sarcopenia and Frailty. Calcified Tissue International, 2013, 93, 101-120.	3.1	310
16	Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis. Archives of Internal Medicine, 2003, 163, 1514.	3.8	309
17	Burden of frailty in the elderly population: perspectives for a public health challenge. Archives of Public Health, 2015, 73, 19.	2.4	297
18	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. Calcified Tissue International, 2019, 105, 1-14.	3.1	295

#	Article	IF	Citations
19	Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Archives of Physical Medicine and Rehabilitation, 2005, 86, 303-307.	0.9	279
20	Does nutrition play a role in the prevention and management of sarcopenia?. Clinical Nutrition, 2018, 37, 1121-1132.	5.0	279
21	Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 2013, 29, 305-313.	1.9	266
22	Value of biomarkers in osteoarthritis: current status and perspectives. Annals of the Rheumatic Diseases, 2013, 72, 1756-1763.	0.9	241
23	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2013, 43, 303-313.	3.4	239
24	Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology, 2021, 17, 59-66.	8.0	233
25	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1-12.	3.1	220
26	Effects of Dairy Products Consumption on Health: Benefits and Beliefsâ€"A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 2016, 98, 1-17.	3.1	210
27	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 2016, 45, S3-S11.	3.4	203
28	Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Annals of the Rheumatic Diseases, 2004, 63, 759-766.	0.9	190
29	Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Experimental Gerontology, 2015, 69, 103-110.	2.8	190
30	Nutritional Status and Nutritional Treatment Are Related to Outcomes and Mortality in Older Adults with Hip Fracture. Nutrients, 2018, 10, 555.	4.1	186
31	Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. Journal of Nutrition, Health and Aging, 2019, 23, 494-502.	3.3	180
32	Osteoporosis and sarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care, 2016, 19, 31-36.	2.5	171
33	The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcified Tissue International, 2017, 100, 229-234.	3.1	171
34	Validation of the SarQoL®, a specific healthâ€related quality of life questionnaire for Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 238-244.	7.3	166
35	Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis and Cartilage, 2015, 23, 851-859.	1.3	155
36	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 15-24.	2.7	146

#	Article	IF	CITATIONS
37	Antidepressant medications and osteoporosis. Bone, 2012, 51, 606-613.	2.9	144
38	Quality of life assessment in musculo-skeletal health. Aging Clinical and Experimental Research, 2018, 30, 413-418.	2.9	144
39	Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis and Cartilage, 2008, 16, 254-260.	1.3	143
40	Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. BMC Musculoskeletal Disorders, 2015, 16, 60.	1.9	139
41	The health economics burden of sarcopenia: a systematic review. Maturitas, 2019, 119, 61-69.	2.4	134
42	The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporosis International, 2017, 28, 447-462.	3.1	130
43	Malnutrition as a Strong Predictor of the Onset of Sarcopenia. Nutrients, 2019, 11, 2883.	4.1	129
44	Vitamin D Analogs Versus Native Vitamin D in Preventing Bone Loss and Osteoporosis-Related Fractures: A Comparative Meta-analysis. Calcified Tissue International, 2005, 76, 176-186.	3.1	127
45	Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. Nutrition Reviews, 2021, 79, 121-147.	5.8	122
46	Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3076-3081.	3.6	119
47	Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 263-268.	1.3	117
48	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 2016, 33, 75-85.	2.7	116
49	Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis. Drugs and Aging, 2007, 24, 573-580.	2.7	115
50	Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone, 2004, 34, 344-351.	2.9	113
51	Estimation of sarcopenia prevalence using various assessment tools. Experimental Gerontology, 2015, 61, 31-37.	2.8	113
52	Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporosis International, 2004, 15, 301-310.	3.1	112
53	Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis International, 2003, 14, 179-190.	3.1	110
54	Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism, 2019, 49, 9-19.	3.4	110

#	Article	IF	Citations
55	Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporosis International, 2013, 24, 121-137.	3.1	106
56	Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 39-46.	0.5	105
57	Social support and health-related quality of life in hip and knee osteoarthritis. Quality of Life Research, 2004, 13, 321-330.	3.1	104
58	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 2004, 11, 138-143.	2.0	104
59	Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8Âyears. Bone, 2009, 45, 1059-1064.	2.9	103
60	Patients' Expectations Impact Their Satisfaction following Total Hip or Knee Arthroplasty. PLoS ONE, 2016, 11, e0167911.	2.5	100
61	Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporosis International, 2011, 22, 2769-2788.	3.1	98
62	Effects of strontium ranelate on spinal osteoarthritis progression. Annals of the Rheumatic Diseases, 2007, 67, 335-339.	0.9	95
63	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. Arthritis Care and Research, 2017, 69, 1287-1296.	3.4	95
64	Maintenance of antifracture efficacy over 10Âyears with strontium ranelate in postmenopausal osteoporosis. Osteoporosis International, 2012, 23, 1115-1122.	3.1	94
65	What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis?. Annals of the Rheumatic Diseases, 2013, 72, 1594-1604.	0.9	91
66	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	2.9	91
67	Osteosarcopenia: where osteoporosis and sarcopenia collide. Rheumatology, 2021, 60, 529-537.	1.9	91
68	Role of glucosamine in the treatment for osteoarthritis. Rheumatology International, 2012, 32, 2959-2967.	3.0	90
69	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 2016, 7, 243-246.	2.8	90
70	Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age and Ageing, 2015, 44, 960-966.	1.6	89
71	Prevalence of vitamin D inadequacy in European postmenopausal women. Current Medical Research and Opinion, 2007, 23, 1939-1944.	1.9	85
72	Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis. Osteoarthritis and Cartilage, 2007, 15, 98-103.	1.3	85

#	Article	IF	Citations
73	Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Archives of Orthopaedic and Trauma Surgery, 2012, 132, 1583-1587.	2.4	85
74	Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and Allâ€Cause Mortality: A Systematic Review and Metaâ€analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2014, 3, e000515.	3.7	85
75	The promise of wearable activity sensors to define patient recovery. Journal of Clinical Neuroscience, 2014, 21, 1089-1093.	1.5	85
76	Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis and Cartilage, 2003, 11, 1-5.	1.3	84
77	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. Drugs and Aging, 2015, 32, 179-187.	2.7	82
78	Comparison of the performance of five screening methods for sarcopenia. Clinical Epidemiology, 2018, Volume 10, 71-82.	3.0	80
79	Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Annals of the Rheumatic Diseases, 2006, 65, 1050-1054.	0.9	78
80	Peanutâ€allergic patients in the <scp>MIRABEL</scp> survey: characteristics, allergists' dietary advice and lessons from real life. Clinical and Experimental Allergy, 2016, 46, 610-620.	2.9	78
81	How to define responders in osteoarthritis. Current Medical Research and Opinion, 2013, 29, 719-729.	1.9	75
82	Reliability of muscle strength measures obtained with a handâ€held dynamometer in an elderly population. Clinical Physiology and Functional Imaging, 2017, 37, 332-340.	1.2	75
83	Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Bone, 2003, 32, 541-545.	2.9	73
84	Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S12-S17.	3.4	73
85	Prediction of Adverse Outcomes in Nursing Home Residents According to Intrinsic Capacity Proposed by the World Health Organization. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1594-1599.	3.6	73
86	Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scandinavian Journal of Rheumatology, 2002, 31, 13-16.	1.1	72
87	The internet as a source of information used by women after childbirth to meet their need for information: A web-based survey. Midwifery, 2017, 48, 46-52.	2.3	72
88	Management of osteoporosis of the oldest old. Osteoporosis International, 2014, 25, 2507-2529.	3.1	71
89	Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 65-99.	2.7	70
90	Management of osteoporosis in the elderly. Current Medical Research and Opinion, 2009, 25, 2373-2387.	1.9	69

#	Article	IF	Citations
91	Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. Value in Health, 2009, 12, 687-696.	0.3	69
92	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International, 2019, 30, 2155-2165.	3.1	69
93	Risk Factors of Overuse Shoulder Injuries in Overhead Athletes: A Systematic Review. Sports Health, 2020, 12, 478-487.	2.7	69
94	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 2019, 30, 45-57.	3.1	67
95	Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clinical Rheumatology, 2020, 39, 861-871.	2.2	67
96	Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 2020, 32, 547-560.	2.9	65
97	Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions. Aging Clinical and Experimental Research, 2018, 30, 307-313.	2.9	64
98	Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. Journal of Rheumatology, 2003, 30, 1043-50.	2.0	64
99	How to manage osteoporosis before the age of 50. Maturitas, 2020, 138, 14-25.	2.4	63
100	Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis and Cartilage, 2005, 13, 13-19.	1.3	62
101	Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 45-64.	2.7	62
102	Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskeletal Disorders, 2008, 9, 165.	1.9	61
103	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60
104	Identifying maternal needs following childbirth: A qualitative study among mothers, fathers and professionals. BMC Pregnancy and Childbirth, 2017, 17, 213.	2.4	59
105	Current role of glucosamine in the treatment of osteoarthritis. Rheumatology, 2007, 46, 731-735.	1.9	58
106	Redesigning care for older people to preserve physical and mental capacity: WHO guidelines on community-level interventions in integrated care. PLoS Medicine, 2019, 16, e1002948.	8.4	57
107	Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 129-143.	2.7	57
108	Association between dietary nutrient intake and sarcopenia in the SarcoPhAge study. Aging Clinical and Experimental Research, 2019, 31, 815-824.	2.9	57

#	Article	IF	Citations
109	EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. Journal of the American Medical Directors Association, 2019, 20, 384-385.	2.5	57
110	The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 2010, 96, 170-177.	3.0	56
111	Effects of vitamin D in the elderly population: current status and perspectives. Archives of Public Health, 2014, 72, 32.	2.4	56
112	Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2018, 30, 111-117.	2.9	56
113	Prediction of the Incidence of Falls and Deaths Among Elderly Nursing Home Residents: The SENIOR Study. Journal of the American Medical Directors Association, 2018, 19, 18-24.	2.5	56
114	Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 25-44.	2.7	56
115	Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1200-1211.	7.3	55
116	Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. Journal of Musculoskeletal Neuronal Interactions, 2014, 14, 425-31.	0.1	55
117	Cost–Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. Value in Health, 2010, 13, 394-401.	0.3	54
118	Relationship between frailty, physical performance and quality of life among nursing home residents: the SENIOR cohort. Aging Clinical and Experimental Research, 2016, 28, 1149-1157.	2.9	54
119	How clinical practitioners assess frailty in their daily practice: an international survey. Aging Clinical and Experimental Research, 2017, 29, 905-912.	2.9	54
120	Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Annals of the Rheumatic Diseases, 2005, 64, 1727-1730.	0.9	53
121	A FRAX® model for the assessment of fracture probability in Belgium. Osteoporosis International, 2011, 22, 453-461.	3.1	53
122	Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the artâ€"outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2019, 31, 1375-1389.	2.9	53
123	Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 101-127.	2.7	53
124	Republished: Value of biomarkers in osteoarthritis: current status and perspectives. Postgraduate Medical Journal, 2014, 90, 171-178.	1.8	52
125	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017. 56. 245-261.	2.3	52
126	Translation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French. Archives of Public Health, 2012, 70, 12.	2.4	51

#	Article	IF	Citations
127	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas, 2017, 96, 54-57.	2.4	51
128	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 2019, 105, 109-124.	3.1	51
129	Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas, 2003, 44, 259-265.	2.4	50
130	Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients. Nephron Clinical Practice, 2014, 128, 127-134.	2.3	50
131	Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Advances in Therapy, 2019, 36, 1085-1099.	2.9	49
132	Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clinical and Experimental Rheumatology, 2004, 22, 36-42.	0.8	49
133	Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone, 2008, 42, 832-836.	2.9	48
134	Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Complementary Therapies in Medicine, 2012, 20, 124-130.	2.7	48
135	Validity and Reliability of the French Version of the STarT Back Screening Tool for Patients With Low Back Pain. Spine, 2014, 39, E123-E128.	2.0	48
136	Relevance of vitamin D in the pathogenesis and therapy of frailty. Current Opinion in Clinical Nutrition and Metabolic Care, 2017, 20, 26-29.	2.5	48
137	Bone Resorption in Post-menopausal Women with Normal and Low BMD Assessed with Biochemical Markers Specific for Telopeptide Derived Degradation Products of Collagen Type I. Calcified Tissue International, 2001, 69, 130-137.	3.1	47
138	Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis and Cartilage, 2015, 23, 2086-2093.	1.3	47
139	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2019, 31, 905-915.	2.9	47
140	Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Current Medical Research and Opinion, 2007, 23, 3041-3045.	1.9	46
141	Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clinical and Experimental Research, 2021, 33, 3-17.	2.9	46
142	Equivalence of a single dose (1200Âmg) compared to a three-time a day dose (400Âmg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis and Cartilage, 2013, 21, 22-27.	1.3	45
143	Transmission of SARS-CoV-2 After COVID-19 Screening and Mitigation Measures for Primary School Children Attending School in Liège, Belgium. JAMA Network Open, 2021, 4, e2128757.	5.9	45
144	The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporosis International, 2016, 27, 2181-2195.	3.1	44

#	Article	IF	Citations
145	A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Current Medical Research and Opinion, 2016, 32, 997-1004.	1.9	44
146	Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. European Journal of Physical and Rehabilitation Medicine, 2017, 53, 633-642.	2.2	44
147	Responders to Platelet-Rich Plasma in Osteoarthritis: A Technical Analysis. BioMed Research International, 2017, 2017, 1-11.	1.9	44
148	Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis and Cartilage, 2006, 14, 963-966.	1.3	42
149	What do we know about the safety of corticosteroids in rheumatoid arthritis?. Current Medical Research and Opinion, 2013, 29, 1147-1160.	1.9	42
150	Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European Journal of Public Health, 2015, 25, 20-25.	0.3	41
151	Equation models developed with bioelectric impedance analysis tools to assess muscle mass: A systematic review. Clinical Nutrition ESPEN, 2020, 35, 47-62.	1.2	41
152	The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women. Maturitas, 2020, 139, 69-89.	2.4	41
153	Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporosis International, 2011, 22, 893-901.	3.1	40
154	Prevalence of vitamin D inadequacy in European women aged over 80 years. Archives of Gerontology and Geriatrics, 2014, 59, 78-82.	3.0	40
155	English translation and validation of the SarQoL $<$ sup $>$ Â $^{\odot}<$ /sup $>$ , a quality of life questionnaire specific for sarcopenia. Age and Ageing, 2017, 46, 271-276.	1.6	40
156	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 2020, 80, 1537-1552.	10.9	40
157	Health Technology Assessment in Osteoporosis. Calcified Tissue International, 2013, 93, 1-14.	3.1	39
158	Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 809-834.	4.7	39
159	Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs, 2020, 80, 1947-1959.	10.9	39
160	Fracture risk following intermission of osteoporosis therapy. Osteoporosis International, 2019, 30, 1733-1743.	3.1	38
161	Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000–2007). Arthritis Care and Research, 2012, 64, 744-750.	3.4	37
162	Adverse Health Events Related to Self-Medication Practices Among Elderly: A Systematic Review. Drugs and Aging, 2017, 34, 359-365.	2.7	37

#	Article	IF	Citations
163	Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcified Tissue International, 2017, 101, 111-131.	3.1	37
164	Primary Prevention of Osteoporosis: Mass Screening Scenario or Prescreening With Questionnaires? An Economic Perspective. Journal of Bone and Mineral Research, 2004, 19, 1955-1960.	2.8	36
165	Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone, 2008, 43, 991-994.	2.9	36
166	Meta-analyses indexed in PsycINFO had a better completeness of reporting when they mention PRISMA. Journal of Clinical Epidemiology, 2019, 115, 46-54.	5.0	36
167	Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine, 2015, 48, 65-68.	2.3	35
168	Grip strength measurement: Towards a standardized approach in sarcopenia research and practice. European Geriatric Medicine, 2016, 7, 247-255.	2.8	34
169	Sarcopenia as a public health problem. European Geriatric Medicine, 2016, 7, 272-275.	2.8	34
170	Bone health assessment in older people with or without muscle health impairment. Osteoporosis International, 2018, 29, 1057-1067.	3.1	33
171	Effects of Protein, Essential Amino Acids, B-Hydroxy B-Methylbutyrate, Creatine, Dehydroepiandrosterone and Fatty Acid Supplementation on Muscle Mass, Muscle Strength and Physical Performance in Older People Aged 60 Years and Over. A Systematic Review of the Literature. Journal of Nutrition, Health and Aging, 2018, 22, 117-130.	3.3	33
172	Mobile Phone-Connected Wearable Motion Sensors to Assess Postoperative Mobilization. JMIR MHealth and UHealth, 2015, 3, e78.	3.7	33
173	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	3.1	33
174	Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 2010, 64, 756-762.	1.7	32
175	Vitamin D and osteosarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care, 2017, 20, 498-503.	2.5	32
176	Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. European Geriatric Medicine, 2018, 9, 23-28.	2.8	32
177	Myostatin and Insulin-Like Growth Factor 1 Are Biomarkers of Muscle Strength, Muscle Mass, and Mortality in Patients on Hemodialysis. , 2019, 29, 511-520.		32
178	Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies. PLoS ONE, 2019, 14, e0216065.	2.5	32
179	Neurofilament light chain concentration in an aging population. Aging Clinical and Experimental Research, 2022, 34, 331-339.	2.9	32
180	Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis and Cartilage, 2003, 11, 730-737.	1.3	31

#	Article	IF	CITATIONS
181	Post-fracture management of patients with hip fracture: a perspective. Current Medical Research and Opinion, 2008, 24, 2841-2851.	1.9	31
182	Effects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents. BMC Geriatrics, 2013, 13, 42.	2.7	31
183	Evaluation of the impact of 6-month training by whole body vibration on the risk of falls among nursing home residents, observed over a 12-month period: a single blind, randomized controlled trial. Aging Clinical and Experimental Research, 2014, 26, 369-376.	2.9	31
184	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs and Aging, 2015, 32, 525-535.	2.7	31
185	Review of the nutritional benefits and risks related to intense sweeteners. Archives of Public Health, 2015, 73, 41.	2.4	31
186	Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions. Journal of the American Medical Directors Association, 2019, 20, 43-46.e2.	2.5	31
187	Return-to-play criteria after hamstring injury: actual medicine practice in professional soccer teams. Journal of Sports Science and Medicine, 2014, 13, 721-3.	1.6	31
188	Vitamin D inadequacy in Belgian postmenopausal osteoporotic women. BMC Public Health, 2007, 7, 64.	2.9	30
189	Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy, 2008, 25, 1235-1256.	2.9	30
190	Towards a better estimate of storage properties of aquifer with magnetic resonance sounding. Journal of Hydrology, 2012, 458-459, 51-58.	5.4	30
191	Current review of the SarQoL $\hat{A}^{\circ}$ : a health-related quality of life questionnaire specific to sarcopenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 335-341.	1.4	30
192	Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Current Rheumatology Reports, 2000, 2, 472-477.	4.7	29
193	Highest Prevalence of Vitamin D Inadequacy in Institutionalized Women Compared with Noninstitutionalized Women: A Case–Control Study. Women's Health, 2009, 5, 49-54.	1.5	29
194	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 271-282.	3.4	29
195	French translation and validation of the sarcopenia screening tool SARC-F. European Geriatric Medicine, 2018, 9, 29-37.	2.8	29
196	Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. Joint Bone Spine, 2018, 85, 609-614.	1.6	29
197	Polish Validation of the SarQoL $\hat{A}^{\otimes}$ , a Quality of Life Questionnaire Specific to Sarcopenia. Journal of Clinical Medicine, 2018, 7, 323.	2.4	29
198	Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort. Calcified Tissue International, 2019, 104, 273-284.	3.1	29

#	Article	IF	CITATIONS
199	Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club. Frontiers in Endocrinology, 0, 13, .	3.5	29
200	Safety concerns with the long-term management of osteoporosis. Expert Opinion on Drug Safety, 2013, 12, 507-522.	2.4	28
201	Cross cultural adaptation of the Greek sarcopenia quality of life (SarQoL) questionnaire. Disability and Rehabilitation, 2020, 42, 1006-1012.	1.8	28
202	Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutrition, 2009, 12, 111-114.	2.2	27
203	Intrinsic Capacity Defined Using Four Domains and Mortality Risk: A 5-Year Follow-Up of the SarcoPhAge Cohort. Journal of Nutrition, Health and Aging, 2022, 26, 23-29.	3.3	27
204	Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3Âyears. Osteoporosis International, 2010, 21, 1031-1036.	3.1	26
205	Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease. BMC Nephrology, 2013, 14, 57.	1.8	26
206	Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs and Aging, 2014, 31, 413-424.	2.7	26
207	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases, 2016, 75, 1268-1271.	0.9	26
208	Psychometric performance of the Romanian version of the SarQoL $\hat{A}^{\otimes}$ , a health-related quality of life questionnaire for sarcopenia. Archives of Osteoporosis, 2017, 12, 103.	2.4	26
209	Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporosis International, 2010, 21, 157-165.	3.1	25
210	Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. Rheumatology, 2014, 53, 1457-1464.	1.9	25
211	Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents. Gait and Posture, 2017, 54, 56-61.	1.4	25
212	Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2018, 48, 1-8.	3.4	25
213	One-year follow-up of platelet-rich plasma infiltration to treat chronic proximal patellar tendinopathies. Acta Orthopaedica Belgica, 2015, 81, 251-6.	0.4	25
214	Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. Cartilage, 2018, 9, 127-139.	2.7	24
215	Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatology and Therapy, 2020, 7, 703-740.	2.3	24
216	Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. Clinical Nutrition, 2021, 40, 2188-2199.	5.0	24

#	Article	IF	Citations
217	Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Current Opinion in Rheumatology, 2003, 15, 651-655.	4.3	23
218	Intravenous paracetamol: a review of efficacy and safety in therapeutic use. Future Neurology, 2007, 2, 673-688.	0.5	23
219	Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75Âyears. Bone, 2010, 46, 440-446.	2.9	23
220	The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Seminars in Arthritis and Rheumatism, 2016, 45, S42-S48.	3.4	23
221	Weight of Evidence for Hazard Identification: A Critical Review of the Literature. Environmental Health Perspectives, 2018, 126, 076001.	6.0	23
222	Evaluation of the Responsiveness of the SarQoL® Questionnaire, a Patient-Reported Outcome Measure Specific to Sarcopenia. Advances in Therapy, 2018, 35, 1842-1858.	2.9	23
223	Patients' preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clinical and Experimental Research, 2019, 31, 1-3.	2.9	23
224	Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. Public Health, 2021, 193, 101-108.	2.9	23
225	The global approach to rehabilitation following an osteoporotic fragility fracture: A review ofÂthe rehabilitation working group of the International Osteoporosis FoundationÂ(IOF) committee of scientific advisors. Osteoporosis International, 2022, 33, 527-540.	3.1	23
226	Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis?. Osteoarthritis and Cartilage, 2003, 11, 87-91.	1.3	22
227	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion, 2015, 31, 1041-1045.	1.9	22
228	Relationship between the changes over time of bone mass and muscle health in children and adults: a systematic review and meta-analysis. BMC Musculoskeletal Disorders, 2019, 20, 429.	1.9	22
229	French translation and validation of the Cumberland Ankle Instability Tool, an instrument for measuring functional ankle instability. Foot and Ankle Surgery, 2020, 26, 391-397.	1.7	22
230	Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study. Calcified Tissue International, 2020, 106, 239-247.	3.1	22
231	Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporosis International, 2010, 21, 233-241.	3.1	21
232	Adherence to a standardized protocol for measuring grip strength and appropriate cut-off values in adults over 65 years with sarcopenia: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2015, 13, 50-59.	1.7	21
233	Energy and nutrient content of food served and consumed by nursing home residents. Journal of Nutrition, Health and Aging, 2017, 21, 727-732.	3.3	21
234	Effects of a giant exercising board game intervention on ambulatory physical activity among nursing home residents: a preliminary study. Clinical Interventions in Aging, 2017, Volume 12, 847-858.	2.9	21

#	Article	IF	Citations
235	Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. Aging Clinical and Experimental Research, 2019, 31, 1163-1167.	2.9	21
236	Meeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions. JMIR Research Protocols, 2017, 6, e76.	1.0	21
237	Impact of the joint space width measurement method on the design of knee osteoarthritis studies. Aging Clinical and Experimental Research, 2003, 15, 136-141.	2.9	20
238	Impact of Malnutrition Status on Muscle Parameter Changes over a 5-Year Follow-Up of Community-Dwelling Older Adults from the SarcoPhAge Cohort. Nutrients, 2021, 13, 407.	4.1	20
239	Strontium ranelate in the prevention of osteoporotic fractures. International Journal of Clinical Practice, 2007, 61, 324-328.	1.7	19
240	Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene. Calcified Tissue International, 2012, 91, 244-249.	3.1	19
241	Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Therapeutic Advances in Musculoskeletal Disease, 2013, 5, 268-276.	2.7	19
242	Cross-cultural adaptation and validation of the Patient-Rated Tennis Elbow Evaluation Questionnaire on lateral elbow tendinopathy for French-speaking patients. Journal of Hand Therapy, 2016, 29, 496-504.	1.5	19
243	Psychometric measurements of AMSTAR 2 in a sample of meta-analyses indexed in PsycINFO. Journal of Clinical Epidemiology, 2020, 119, 144-145.	5.0	19
244	Development and Validation of the ORACLE Score to Predict Risk of Osteoporosis. Mayo Clinic Proceedings, 2004, 79, 1402-1408.	3.0	18
245	Symptom and Structure Modifying Properties of Chondroitin Sulfate in Osteoarthritis. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1051-1061.	2.4	18
246	Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. European Journal of Epidemiology, 2009, 24, 707-712.	5.7	18
247	Validation of an extended French version of ID Migraineâ,,¢ as a migraine-screening tool. Cephalalgia, 2015, 35, 437-442.	3.9	18
248	Hand grip strength measurement in haemodialysis patients: before or after the session?. CKJ: Clinical Kidney Journal, 2018, 11, 555-558.	2.9	18
249	Sarcopenia quality-of-life questionnaire (SarQoL) $\hat{A}^{@}$ : translation, cross-cultural adaptation and validation in Turkish. Aging Clinical and Experimental Research, 2021, 33, 2979-2988.	2.9	18
250	Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 2021, 33, 1507-1517.	2.9	18
251	Translation and validation of the Dutch SarQoL, a quality of life questionnaire specific to sarcopenia. Journal of Musculoskeletal Neuronal Interactions, 2018, 18, 463-472.	0.1	18
252	Do Estrogens Effectively Prevent Osteoporosis-Related Fractures?. Calcified Tissue International, 2000, 67, 191-194.	3.1	17

#	Article	IF	CITATIONS
253	Monitoring of osteoporosis therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 835-841.	4.7	17
254	Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1942-1942.	0.9	17
255	Cross-cultural Adaptation and Validation of the Victorian Institute of Sport Assessment-Patella Questionnaire for French-Speaking Patients With Patellar Tendinopathy. Journal of Orthopaedic and Sports Physical Therapy, 2016, 46, 384-390.	3.5	17
256	Does negative information about aging influence older adults' physical performance and subjective age?. Archives of Gerontology and Geriatrics, 2018, 78, 181-189.	3.0	17
257	Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. International Journal of Rheumatic Diseases, 2019, 22, 376-385.	1.9	17
258	Prevalence of Frailty in Nursing Home Residents According to Various Diagnostic Tools. Journal of Frailty & Early, Aging, the, 2017, 6, 122-128.	1.3	17
259	High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. Journal of Rheumatology, 2016, 43, 657-665.	2.0	16
260	Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the "need for surgeryâ€. Aging Clinical and Experimental Research, 2018, 30, 315-321.	2.9	16
261	Sarcopenia: Performance of the SARC-F Questionnaire According to the European Consensus Criteria, EWGSOP1 and EWGSOP2. Journal of the American Medical Directors Association, 2019, 20, 1182-1183.	2.5	16
262	Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatology International, 2019, 39, 1117-1123.	3.0	16
263	Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. Aging Clinical and Experimental Research, 2022, 34, 223-234.	2.9	16
264	Vitamin D inadequacy in French osteoporotic and osteopenic women. Joint Bone Spine, 2008, 75, 567-572.	1.6	15
265	Assessment of determinants for osteoporosis in elderly men. Osteoporosis International, 2009, 20, 1157-1166.	3.1	15
266	Changes in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years. Calcified Tissue International, 2013, 93, 502-507.	3.1	15
267	Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis. Advances in Therapy, 2016, 33, 2257-2268.	2.9	15
268	Skeletal health in breast cancer survivors. Maturitas, 2017, 105, 78-82.	2.4	15
269	Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months' Follow-up. Clinical Breast Cancer, 2018, 18, e1189-e1204.	2.4	15
270	Validation of the Lithuanian version of sarcopenia-specific quality of life questionnaire (SarQoL $\hat{A}^{\otimes}$ ). European Geriatric Medicine, 2019, 10, 761-767.	2.8	15

#	Article	IF	Citations
271	Gait symmetry in the dual task condition as a predictor of future falls among independent older adults: a 2-year longitudinal study. Aging Clinical and Experimental Research, 2019, 31, 1057-1067.	2.9	15
272	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs and Aging, 2019, 36, 145-159.	2.7	15
273	Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clinical and Experimental Research, 2019, 31, 881-887.	2.9	15
274	Association between Changes in Nutrient Intake and Changes in Muscle Strength and Physical Performance in the SarcoPhAge Cohort. Nutrients, 2020, 12, 3485.	4.1	15
275	Best-worst scaling identified adequate statistical methods and literature search as the most important items of AMSTAR2 (A measurement tool to assess systematic reviews). Journal of Clinical Epidemiology, 2020, 128, 74-82.	<b>5.</b> 0	15
276	Exposure to magnetic fields and childhood leukemia: a systematic review and meta-analysis of case-control and cohort studies. Reviews on Environmental Health, 2023, 38, 229-253.	2.4	15
277	Combination/sequential therapy in osteoporosis. Current Osteoporosis Reports, 2004, 2, 123-130.	3.6	14
278	Data set of healthy old people assessed for three walking conditions using accelerometric and opto-electronic methods. Aging Clinical and Experimental Research, 2017, 29, 1201-1209.	2.9	14
279	Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Annals of the Rheumatic Diseases, 2018, 77, e39-e39.	0.9	14
280	Glucosamine sulphate: an umbrella review of health outcomes. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097592.	2.7	14
281	Prevalence of Concomitant Bone and Muscle Wasting in Elderly Women from the SarcoPhAge Cohort: Preliminary Results. Journal of Frailty & Ding, the, 2017, 6, 18-23.	1.3	14
282	Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. Aging Clinical and Experimental Research, 2022, 34, 481-483.	2.9	14
283	Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone, 2012, 51, 674-679.	2.9	13
284	Can New Information and Communication Technologies Help in the Management of Osteoporosis?. Women's Health, 2014, 10, 229-232.	1.5	13
285	Cross-cultural translation, validity, and reliability of the French version of the Neurophysiology of Pain Questionnaire. Physiotherapy Theory and Practice, 2017, 33, 880-887.	1.3	13
286	Influence of environmental factors on food intake among nursing home residents: a survey combined with a video approach. Clinical Interventions in Aging, 2017, Volume 12, 1055-1064.	2.9	13
287	Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 147-160.	1.4	13
288	Outcome Priorities for Older Persons With Sarcopenia. Journal of the American Medical Directors Association, 2020, 21, 267-271.e2.	2.5	13

#	Article	IF	Citations
289	A systematic review of prediction models to diagnose COVID-19 in adults admitted to healthcare centers. Archives of Public Health, 2021, 79, 105.	2.4	13
290	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Archives of Osteoporosis, 2022, 17, .	2.4	13
291	Mirabel: An integrated project for risk and cost/benefit analysis of peanut allergy. Regulatory Toxicology and Pharmacology, 2015, 71, 178-183.	2.7	12
292	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. European Geriatric Medicine, 2016, 7, 519-525.	2.8	12
293	Determinants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners. Osteoporosis International, 2016, 27, 881-886.	3.1	12
294	Own attitude toward aging among nursing home residents: results of the SENIOR cohort. Aging Clinical and Experimental Research, 2018, 30, 1151-1159.	2.9	12
295	Relationship between peak expiratory flow and incidence of frailty, deaths and falls among nursing home residents: Results of the SENIOR cohort. Archives of Gerontology and Geriatrics, 2019, 85, 103913.	3.0	12
296	2021 revised algorithm for the management of knee osteoarthritisâ€"the Chinese viewpoint. Aging Clinical and Experimental Research, 2021, 33, 2141-2147.	2.9	12
297	Strontium ranelate normalizes bone mineral density in osteopenic patients. Aging Clinical and Experimental Research, 2007, 19, 330-333.	2.9	11
298	Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. Journal of Medical Economics, 2009, 12, 356-360.	2.1	11
299	Aesthetic discomfort in hand osteoarthritis: results from the LIÃ ge Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 2015, 17, 346.	3.5	11
300	Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11). Archives of Osteoporosis, 2015, 10, 11.	2.4	11
301	Using supervised learning machine algorithm to identify future fallers based on gait patterns: A two-year longitudinal study. Experimental Gerontology, 2019, 127, 110730.	2.8	11
302	Clinical Impact of Nutritional Status and Energy Balance in Elderly Hospitalized Patients. Journal of Nutrition, Health and Aging, 2020, 24, 1073-1079.	3.3	11
303	The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: A pilot interventional study. Experimental Gerontology, 2020, 138, 110983.	2.8	11
304	Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the SENIOR cohort. Journal of Musculoskeletal Neuronal Interactions, 2017, 17, 209-217.	0.1	11
305	An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for theÂldentification of Patients with Osteoporosis. Disease Management and Health Outcomes, 2008, 16, 429-438.	0.4	10
306	The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2010, 21, 713-722.	3.1	10

#	Article	IF	Citations
307	Large review finds no clinically important effect of glucosamine or chondroitin on pain in people with osteoarthritis of the knee or hip but results are questionable and likely due to heterogeneity. Evidence-Based Medicine, $2011, 16, 52-53$ .	0.6	10
308	Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women. Bone, 2012, 50, 1201-1202.	2.9	10
309	Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis International, 2013, 24, 2291-2300.	3.1	10
310	Clinical Trials Using Mobile Health Applications. Pharmaceutical Medicine, 2015, 29, 17-25.	1.9	10
311	What should a website dedicated to the postnatal period contain? A Delphi survey among parents and professionals. Midwifery, 2017, 53, 9-14.	2.3	10
312	Physical performance trajectories and mortality among nursing home residents: results of the SENIOR cohort. Age and Ageing, 2020, 49, 800-806.	1.6	10
313	RELATIONSHIP BETWEEN ISOMETRIC STRENGTH OF SIX LOWER LIMB MUSCLE GROUPS AND MOTOR SKILLS AMONG NURSING HOME RESIDENTS. Journal of Frailty & Samp; Aging, the, 2015, 4, 1-4.	1.3	10
314	Cost–effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 359-366.	1.4	9
315	P346: Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. European Geriatric Medicine, 2014, 5, S191.	2.8	9
316	Development and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis. Journal of Orthopaedics, 2015, 12, 46-57.	1.3	9
317	Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 571-578.	1.4	9
318	The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard―by Clark et al Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1272-1274.	7.3	9
319	SUBJECTIVE SLEEP QUALITY AMONG SARCOPENIC AND NON-SARCOPENIC OLDER ADULTS: RESULTS FROM THE SARCOPHAGE COHORT. Journal of Frailty & Samp; Aging, the, 2018, 7, 1-6.	1.3	9
320	Cross-sectional Evaluation of the Sarcopenia Quality of Life (SarQoL) Questionnaire: Translation and Validation of its Psychometric Properties. Annals of Geriatric Medicine and Research, 2020, 24, 139-147.	1.8	9
321	Lifestyle approaches to prevent and retard sarcopenia: A narrative review. Maturitas, 2022, 161, 44-48.	2.4	9
322	Estimating storage properties of aquifer with magnetic resonance sounding: a field verification in northern Cambodia of the gravitational water apparent cutoff time concept. Near Surface Geophysics, 2014, 12, 211-218.	1.2	8
323	Patient engagement in clinical research through mobile technology. Clinical Practice (London,) Tj ETQq $1\ 1\ 0.784$	314 rgBT / 0.1	Oyerlock 10
324	A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods. Osteoporosis International, 2015, 26, 2863-2868.	3.1	8

#	Article	IF	Citations
325	Critical analytical evaluation of promising markers for sarcopenia. European Geriatric Medicine, 2016, 7, 239-242.	2.8	8
326	Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 2018, 19, 159-161.	1.8	8
327	French translation and validation of the "Anterior Knee Pain Scale―(AKPS). Disability and Rehabilitation, 2019, 41, 1089-1094.	1.8	8
328	Comparing health insurance data and health interview survey data for ascertaining chronic disease prevalence in Belgium. Archives of Public Health, 2020, 78, 120.	2.4	8
329	French Translation and Validation of the Victorian Institute of Sports Assessment for Gluteal Tendinopathy Questionnaire. PM and R, 2021, 13, 137-143.	1.6	8
330	Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL $\hat{A}^{\otimes}$ questionnaire. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 319-330.	7.3	8
331	Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture. Rheumatology International, 2013, 33, 979-983.	3.0	7
332	Added value of a triaxial accelerometer assessing gait parameters to predict falls and mortality among nursing home residents: A two-year prospective study. Technology and Health Care, 2015, 23, 195-203.	1.2	7
333	A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Statistical Methods in Medical Research, 2016, 25, 400-412.	1.5	7
334	Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opinion on Pharmacotherapy, 2017, 18, 1811-1813.	1.8	7
335	French translation and validation of the Achilles Tendon Total Rupture Score "ATRS― Foot and Ankle Surgery, 2020, 26, 662-668.	1.7	7
336	A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCEO working group. Seminars in Arthritis and Rheumatism, 2020, 50, 859-866.	3 <b>.</b> 4	7
337	Methodological quality of meta-analyses indexed in PsycINFO: leads for enhancements: a meta-epidemiological study. BMJ Open, 2020, 10, e036349.	1.9	7
338	Biochemical Markers in Glucocorticoid-Induced Osteoporosis. , 2002, 30, 49-59.		6
339	Strontium ranelate: New data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 2009, 7, 96-102.	3.6	6
340	Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2012, 23, 193-199.	3.1	6
341	Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria. Rheumatology International, 2013, 33, 973-978.	3.0	6
342	International endorsement of the ESCEO algorithm for management of knee osteoarthritis in clinical practice. Seminars in Arthritis and Rheumatism, 2017, 47, e10.	3.4	6

#	Article	IF	CITATIONS
343	Assessing gait parameters with accelerometer-based methods to identify older adults at risk of falls: a systematic review. European Geriatric Medicine, 2018, 9, 435-448.	2.8	6
344	Patient's Engagement in the Identification of Critical Outcomes in Sarcopenia. Journal of the American Medical Directors Association, 2020, 21, 284-286.	2.5	6
345	The "Ankle Instability Instrument― Cross-cultural adaptation and validation in French. Foot and Ankle Surgery, 2021, 27, 70-76.	1.7	6
346	Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL. Quality of Life Research, 2021, 30, 2349-2362.	3.1	6
347	Assessment of the performance of the SarQoL® questionnaire in screening for sarcopenia in older people. Aging Clinical and Experimental Research, 2021, 33, 2149-2155.	2.9	6
348	Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial. Biomolecules, 2021, 11, 1498.	4.0	6
349	Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study. Vaccines, 2022, 10, 899.	4.4	6
350	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca. Arthritis and Rheumatism, 2006, 54, 2339-2341.	6.7	5
351	Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 941-951.	3.3	5
352	Vitamin D Status and Response to Antiosteoporotic Therapy. Women's Health, 2008, 4, 445-447.	1.5	5
353	RETURN-TO-PLAY CRITERIA AFTER HAMSTRING INJURY: ACTUAL MEDICINE PRACTICE IN PROFESSIONAL SOCCER TEAMS. British Journal of Sports Medicine, 2013, 47, e3.53-e3.	6.7	5
354	Adaptation transculturelle et validation des questionnaires VISA-P et VISA-A en français. Science and Sports, 2016, 31, 65-72.	0.5	5
355	Pharmaceutical-grade chondroitin sulfate in the management of knee osteoarthritis. Expert Opinion on Pharmacotherapy, 2018, 19, 409-412.	1.8	5
356	Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss. Arthritis Care and Research, 2019, 71, 300-307.	3.4	5
357	French translation and validation of the exercise-induced leg pain Questionnaire. Disability and Rehabilitation, 2020, 42, 857-862.	1.8	5
358	Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial. Advances in Therapy, 2021, 38, 2271-2283.	2.9	5
359	Assessing polypharmacy in the older population: Comparison of a selfâ€reported and prescription based method. Pharmacoepidemiology and Drug Safety, 2021, 30, 1716-1726.	1.9	5
360	Translation and psychometric performance of the Serbian version of the Sarcopenia Quality of Life (SarQoL®) questionnaire. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 742-748.	0.2	5

#	Article	IF	Citations
361	Normative data for isometric strength of 8 different muscle groups and their usefulness as a predictor of loss of autonomy among physically active nursing home residents: the SENIOR cohort. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 258-265.	0.1	5
362	Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 133-143.	2.7	4
363	Risk of Hip Fracture in Community-dwelling and Institutionalized Osteoporotic Patients: A 3-year Study. International Journal of Gerontology, 2013, 7, 167-170.	0.6	4
364	The International Registry of patients with sarcopenia: applying research in sarcopenia to clinical practice. European Geriatric Medicine, 2018, 9, 735-738.	2.8	4
365	Plasma Klotho and Mortality Risk Among Nursing Home Residents: Results From the SENIOR Cohort. Journal of the American Medical Directors Association, 2018, 19, 1139-1140.	2.5	4
366	Assessment of the energy expenditure of Belgian nursing home residents using indirect calorimetry. Nutrition, 2019, 57, 12-16.	2.4	4
367	Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients. Disability and Rehabilitation, 2020, 42, 2076-2082.	1.8	4
368	What Are the Main Risk Factors for Lower Extremity Running-Related Injuries? A Retrospective Survey Based on 3669 Respondents. Orthopaedic Journal of Sports Medicine, 2021, 9, 232596712110434.	1.7	4
369	Current concepts in the therapeutic management of osteoarthritis with glucosamine. Bulletin of the Hospital for Joint Diseases, 2005, 63, 31-6.	0.3	4
370	Post-intensive care screening: French translation and validation of the Healthy Aging Brain Care-Monitor, hybrid version. Health and Quality of Life Outcomes, 2022, 20, 59.	2.4	4
371	Clinical prediction models for diagnosis of COVID-19 among adult patients: a validation and agreement study. BMC Infectious Diseases, 2022, 22, 464.	2.9	4
372	Oral calcitonin in the management of osteoarthritis: hope or fantasy?. International Journal of Clinical Rheumatology, 2010, 5, 53-58.	0.3	3
373	The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density: reply to Stepan et al Osteoporosis International, 2010, 21, 1039-1040.	3.1	3
374	Rehabilitation in osteoarthritis. Therapy: Open Access in Clinical Medicine, 2010, 7, 669-674.	0.2	3
375	Exploring the Interest in and the Usage of the Internet Among Patients Eligible for Osteoporosis Screening. Calcified Tissue International, 2015, 96, 518-526.	3.1	3
376	Occurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study. Calcified Tissue International, 2017, 101, 465-472.	3.1	3
377	<i>The Authors reply</i> : "Dual energy Xâ€ray absorptiometry: gold standard for muscle mass?―by Scafoglieri et al Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 788-790.	7.3	3
378	Motivational climate of group exercise sessions in nursing homes. Archives of Public Health, 2020, 78, 43.	2.4	3

#	Article	IF	Citations
379	Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). Aging Clinical and Experimental Research, 2021, 33, 1079-1083.	2.9	3
380	Cost-Effectiveness Assessment of Different Glucosamines in Patients with Knee Osteoarthritis: A Simulation Model Adapted to Germany. Current Aging Science, 2021, 14, 242-248.	1.2	3
381	Identifying maternal needs following childbirth: comparison between pregnant women and recent mothers. BMC Pregnancy and Childbirth, 2021, 21, 405.	2.4	3
382	Decision-based interactive model to determine re-opening conditions of a large university campus in Belgium during the first COVID-19 wave. Archives of Public Health, 2022, 80, 71.	2.4	3
383	Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study.  Aging Clinical and Experimental Research, 2022, 34, 1613-1625.	2.9	3
384	Both weight-bearing and non-weight-bearing exercise improved function in patients with knee osteoarthritis. Evidence-Based Medicine, 2009, 14, 178-178.	0.6	2
385	Words, words, words. Archives of Public Health, 2011, 69, 1.	2.4	2
386	Health claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science. Current Medical Research and Opinion, 2012, 28, 611-616.	1.9	2
387	P-197: Development and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQoL. European Geriatric Medicine, 2015, 6, S84.	2.8	2
388	Pratique de l'ostéosynthèse des fractures de jambe en République démocratique du Congo. Revue De Chirurgie Orthopedique Et Traumatologique, 2016, 102, 306-309.	0.0	2
389	CAPTURE THE FRACTURE: INTEGRATED CARE PREVENTS THE DECREASE IN INTRINSIC CAPACITY IN ELDERLY SUBJECTS. Innovation in Aging, 2017, 1, 692-692.	0.1	2
390	Energy Expenditure of Nursing Home Residents and Participation in Exercise Classes: An Analysis of the SENIOR Cohort. Journal of the American Medical Directors Association, 2019, 20, 1183-1184.	2.5	2
391	Importance of Safety in the Management of Osteoarthritis and the Need for Updated Meta-Analyses and Recommendations for Reporting of Harms. Drugs and Aging, 2019, 36, 3-6.	2.7	2
392	Impact of frailty status on the cost of drugs and dietary supplements prescribed to nursing home residents: the SENIOR cohort. Aging Clinical and Experimental Research, 2019, 31, 875-880.	2.9	2
393	Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial. Advances in Therapy, 2020, 37, 4641-4648.	2.9	2
394	Senior physical activity contests in nursing homes: a feasibility study. Aging Clinical and Experimental Research, 2020, 32, 869-876.	2.9	2
395	Validation of the Perform-FES: a new fear of falling scale for hospitalized geriatric patients. Aging Clinical and Experimental Research, 2021, 33, 67-76.	2.9	2
396	Validity of self-reported mammography uptake in the Belgian health interview survey: selection and reporting bias. European Journal of Public Health, 2021, 31, 214-220.	0.3	2

#	Article	IF	CITATIONS
397	Self-Medication Practice among Amateur Runners: Prevalence and Associated Factors. Journal of Sports Science and Medicine, 2016, 15, 387-8.	1.6	2
398	Bone forming agents for the management of osteoporosis. Panminerva Medica, 2014, 56, 97-114.	0.8	2
399	Population screening for fracture risk in postmenopausal women $\hat{a}\in$ " a logical step in reducing the osteoporotic fracture burden?. Osteoporosis International, 0, , .	3.1	2
400	Injectable Bisphosphonates for the Treatment of Osteoporosis. Women's Health, 2007, 3, 719-723.	1.5	1
401	lbandronate in the Management of Postmenopausal Osteoporosis. Clinical Medicine Therapeutics, 2009, 1, CMT.S2354.	0.1	1
402	The need for economic evaluation in osteoarthritis. Aging Health, 2009, 5, 591-954.	0.3	1
403	Is there potential for strontium ranelate in the management of osteoarthritis?. Clinical Practice (London, England), 2013, 10, 201-207.	0.1	1
404	AB1371â€Severity of incident vertebral fracture and future fracture risk: A 3-year prospective study. Annals of the Rheumatic Diseases, 2013, 71, 716.6-716.	0.9	1
405	Micro factors bringing the pharmaceutical industry to a seismic shaking <i>a qualitative research</i> Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 267-274.	1.4	1
406	Response to: Comment on "Responders to Platelet-Rich Plasma in Osteoarthritis: A Technical Analysis― BioMed Research International, 2018, 2018, 1-2.	1.9	1
407	I028â $€f$ Non-pharmacological therapies for the management of osteosarcopenia. Rheumatology, 2019, 58, .	1.9	1
408	Vitamin D for the older patient. Current Opinion in Clinical Nutrition and Metabolic Care, 2020, 23, 4-7.	2.5	1
409	Determining individual trajectories of joint space loss: improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoarthritis and Cartilage, 2021, 29, 59-67.	1.3	1
410	An Assessment of the Toulouse Saint Louis University Mini Falls Assessment Tool to Predict Incident Falls among Older Adults Residing in Nursing Homes: A 6-Month Prospective Study. Journal of Nutrition, Health and Aging, 2021, 25, 933-937.	3.3	1
411	306Association between polypharmacy and mortality in the community-dwelling older population: a data linkage study. International Journal of Epidemiology, 2021, 50, .	1.9	1
412	Effectiveness of protective measures on dental care utilization: analysis from linked database. European Journal of Public Health, 2020, 30, .	0.3	1
413	Experimental Approach of Quadriceps Strength Measurement: Implications for Assessments in Critically Ill Survivors. Diagnostics, 2022, 12, 202.	2.6	1
414	Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial. Rheumatology and Therapy, 2022, 9, 1119-1128.	2.3	1

#	Article	IF	CITATIONS
415	Glucosamine Sulphate in Osteoarthritis: From Symptoms to Structure Modification. Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents, 2005, 4, 217-220.	0.4	O
416	Highlights from The Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Expert Opinion on Pharmacotherapy, 2007, 8, 1779-1784.	1.8	0
417	MD4 COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING COMBINED WITH ALENDRONATE THERAPY FOR THOSE WHO HAVE OSTEOPOROSIS. Value in Health, 2007, 10, A236.	0.3	0
418	POS6 COST-EFFECTIVENESS OF OSTEOPOROSIS SCREENING CAMPAIGN FOR BELGIAN WOMEN. Value in Health, 2007, 10, A395.	0.3	0
419	PMS59 THE CLINICAL AND ECONOMIC BURDEN OF NONADHERENCE WITH OSTEOPOROSIS MEDICATIONS. Value in Health, 2009, 12, A444.	0.3	O
420	PMS9 TREND OF HIP FRACTURE INCIDENCE IN BELGIUM BETWEEN 2000 AND 2007 AND FUTURE PROJECTIONS. Value in Health, 2010, 13, A303-A304.	0.3	0
421	Strontium ranelate increases the number of patients with improvement in osteoarthritis symptoms compared to placebo in the SEKOIA study. Osteoarthritis and Cartilage, 2013, 21, S143.	1.3	O
422	SAT0343â€Severe prevalent vertebral fractures predict subsequent vertebral and non-vertebral fractures: A 3-year prospective study. Annals of the Rheumatic Diseases, 2013, 71, 588.2-588.	0.9	0
423	AB0959â€Radiological and clinical profil of osteoarthritic patients undergoing total joint replacement. Annals of the Rheumatic Diseases, 2013, 71, 693.10-693.	0.9	O
424	AB1372â€Perception, knowledge and use by general practitioners of belgium of the frax® tool. Annals of the Rheumatic Diseases, 2013, 71, 716.7-716.	0.9	0
425	AB1373â€A very high prevalence of vitamin D inadequacy combined with low dietary calcium intake is found in european postmenopausal women. Annals of the Rheumatic Diseases, 2013, 71, 716.8-716.	0.9	O
426	AB0958â€Assessment of quality of life in patients undergoing total joint replacement for OA of the lower limb. Annals of the Rheumatic Diseases, 2013, 71, 693.9-693.	0.9	0
427	SAT0349â€Relationships between changes in bone mineral density and vertebral fractures incidence: An analysis of the last 2 years of a 10-year treatment with strontium ranelate. Annals of the Rheumatic Diseases, 2013, 71, 590.2-590.	0.9	O
428	SAT0341â€Strontium Ranelate Improves Osteoarthritis Symptoms Compared to Placebo in Patients with Knee OA - The Sekoia Study. Annals of the Rheumatic Diseases, 2013, 72, A698.2-A699.	0.9	0
429	The effects of vitamin D on skeletal muscle strength: a meta-analysis of randomized controlled trials. European Journal of Public Health, 2013, 23, .	0.3	O
430	Strontium ranelate decreases the number of rapid radiological progressors from the first year in sekoia study. Osteoarthritis and Cartilage, 2014, 22, S461.	1.3	0
431	THU0210 Impact of Components of the Metabolic Syndrome on Knee Osteoarthritis Progression in the SEKOIA Study. Annals of the Rheumatic Diseases, 2014, 73, 254.2-254.	0.9	O
432	Mirabel Project: Description of a French Population of 785 Peanut Allergic or Sensitized Patients. Journal of Allergy and Clinical Immunology, 2015, 135, AB34.	2.9	0

#	Article	lF	CITATIONS
433	AB1230-HPRâ€Baseline Characteristics of the Lià ge Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 2015, 74, 1346.1-1346.	0.9	O
434	OP0110â€Assessment and Determinants of Aesthetic Discomfort in Hand Osteoarthritis: The Liège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 2015, 74, 110.1-110.	0.9	0
435	Letter to the Editor. Seminars in Arthritis and Rheumatism, 2015, 44, e15.	3.4	0
436	Should your Algorithm Include Plasma Rich in Growth Factors in the Light of Its Clinical Efficacy and Safety?. Seminars in Arthritis and Rheumatism, 2015, 44, e12-e13.	3.4	0
437	Re: Kucharz EJ, Kovalenko V, Szántó S, etÂal. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016;32:997-1004. Current Medical Research and Opinion. 2016. 32. 1771-1772.	1.9	0
438	PRM263 - THE USE OF PRISMA STATEMENT IMPROVES THE REPORTING QUALITY OF META-ANALYSES PUBLISHED IN THE FIELD OF PSYCHOLOGY. Value in Health, 2018, 21, S401.	0.3	0
439	PRM198 - STANDARD ERROR OF MEASUREMENT AND SMALLEST DETECTABLE CHANGE OF THE SARQOL® QUESTIONNAIRE: AN ANALYSIS OF SUBJECTS FROM 8 VALIDATION STUDIES. Value in Health, 2018, 21, S390.	0.3	0
440	Poor quality reporting of the meta-analyses in psychology as assessed using the PRISMA Statement. European Journal of Public Health, 2018, 28, .	0.3	0
441	The "Happy-Mums―website dedicated to the perinatal period: Evaluation of its acceptability by parents and professionals. Midwifery, 2018, 66, 17-24.	2.3	0
442	Fragility fracture risk prediction in elderly people based on a microRNA panel. Clinica Chimica Acta, 2019, 493, S168-S169.	1.1	0
443	Symptomatic efficacy of oral chondroltin sulfate in knee osteoarthritls. A systematic review and meta-analysls of randomized, placebo-controlled trials. Osteoarthritis and Cartilage, 2019, 27, S498-S499.	1.3	0
444	Safety of oral chondroitin sulfate in the management of knee osteoarthritis: results of a new meta-analysis of randomlzed. Placebo-controlled trials. Osteoarthritis and Cartilage, 2019, 27, S499.	1.3	0
445	Predictors of nursing-home entry for elders in Belgium. European Journal of Public Health, 2019, 29, .	0.3	0
446	Impact du traitement par statines dans la progression radiologique de la gonarthroseÂ: résultats issus de l'analyse post-hoc de l'essai SEKOIA. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 81-86.	0.0	0
447	The Role of Nutrition in Bone Health. , 2021, , 39-52.		0
448	Patients' preferences for quality-of-life aspects in sarcopenia: a best–worst scaling study. European Geriatric Medicine, 2021, , 1.	2.8	0
449	Assessment of structure-modifying drugs in osteoarthritis: surrogate or hard clinical end points?. Future Rheumatology, 2006, 1, 199-206.	0.2	0
450	STRONTIUM RANELATE DECREASES VERTEBRAL FRACTURE RISK WHATEVER THE LEVEL OF PRETREATMENT BONE TURNOVER MARKERS. Osteoporosis and Bone Diseases, 2007, 10, 27.	1.4	0

#	ARTICLE	IF	CITATIONS
451	STRONTIUM RANELATE PREVENTS SPINE OSTEOARTHRITIS PROGRESSION IN PATIENTS WITH PREVALENT SPINAL OSTEOARTHRITIS. Osteoporosis and Bone Diseases, 2007, 10, 25.	1.4	0
452	Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. Blood, 2013, 122, 3633-3633.	1.4	0
453	Epidemiological Product Assessment. , 2017, , 85-104.		0
454	FRIO531â€Determinants of clinical and radiological progression of hand osteoarthritis over 2 years. , 2018, , .		0
455	Discriminative power of the Sarcopenia Quality of Life (SarQoL®) questionnaire with the EWGSOP2 criteria. Journal of Frailty & Discriminative power of the Sarcopenia Quality of Life (SarQoL®) questionnaire with the EWGSOP2 criteria.	1.3	0
456	Cross-cultural adaptation and validation of the Greek Version of the SARC-F for evaluating sarcopenia in Greek older adults. Journal of Musculoskeletal Neuronal Interactions, 2020, 20, 505-512.	0.1	0
457	Should We Worry About Nutrition Of Adults With Minor Burns? An Audit Of Their Intakes. Annals of Burns and Fire Disasters, 2021, 34, 163-169.	0.3	0
458	Quality of life and sarcopenic patients Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement, 2022, , .	0.0	0